Mirae Asset Global Investments Co. Ltd. Raises Stock Position in Veeva Systems Inc. $VEEV

Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 139.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 7,656 shares of the technology company’s stock after acquiring an additional 4,454 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Veeva Systems were worth $2,281,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of VEEV. Vanguard Group Inc. boosted its holdings in Veeva Systems by 1.4% in the 2nd quarter. Vanguard Group Inc. now owns 14,971,425 shares of the technology company’s stock worth $4,311,471,000 after buying an additional 210,859 shares during the last quarter. Alliancebernstein L.P. lifted its position in shares of Veeva Systems by 3.7% in the second quarter. Alliancebernstein L.P. now owns 5,705,648 shares of the technology company’s stock valued at $1,643,113,000 after acquiring an additional 205,997 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Veeva Systems by 2.6% in the second quarter. JPMorgan Chase & Co. now owns 3,316,274 shares of the technology company’s stock worth $955,030,000 after acquiring an additional 85,516 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Veeva Systems by 3.8% in the second quarter. Geode Capital Management LLC now owns 3,092,539 shares of the technology company’s stock worth $888,108,000 after acquiring an additional 114,003 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Veeva Systems by 111.7% during the second quarter. AQR Capital Management LLC now owns 1,838,046 shares of the technology company’s stock worth $526,508,000 after purchasing an additional 969,905 shares in the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

Insider Transactions at Veeva Systems

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,000 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $231.43, for a total transaction of $231,430.00. Following the completion of the transaction, the insider owned 23,204 shares of the company’s stock, valued at $5,370,101.72. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 10.30% of the company’s stock.

Veeva Systems Stock Performance

VEEV stock opened at $190.60 on Wednesday. Veeva Systems Inc. has a one year low of $186.40 and a one year high of $310.50. The firm has a market cap of $31.33 billion, a PE ratio of 37.08, a PEG ratio of 1.41 and a beta of 1.08. The firm’s 50 day moving average price is $225.60 and its 200-day moving average price is $263.33.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Thursday, November 20th. The technology company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.09. Veeva Systems had a return on equity of 13.68% and a net margin of 27.93%.The company had revenue of $0.81 million during the quarter, compared to analyst estimates of $792.37 million. During the same period in the prior year, the business posted $1.75 earnings per share. The firm’s revenue for the quarter was up 16.0% compared to the same quarter last year. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. Equities research analysts predict that Veeva Systems Inc. will post 4.35 EPS for the current fiscal year.

Veeva Systems declared that its board has approved a stock repurchase program on Monday, January 5th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the technology company to purchase up to 5.5% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wells Fargo & Company decreased their price objective on Veeva Systems from $341.00 to $333.00 and set an “overweight” rating on the stock in a report on Tuesday, November 25th. William Blair reissued an “outperform” rating on shares of Veeva Systems in a research note on Friday, October 17th. The Goldman Sachs Group initiated coverage on shares of Veeva Systems in a report on Tuesday, January 13th. They issued a “sell” rating and a $215.00 price objective for the company. Truist Financial raised shares of Veeva Systems from a “hold” rating to a “buy” rating in a research note on Thursday, January 8th. Finally, Robert W. Baird upped their price target on Veeva Systems from $314.00 to $319.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. Eighteen investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $308.04.

Veeva Systems Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.